The Food and Drug Administration’s Oncologic Drugs Advisory Committee voted in favor of the agency approving belantamab mafodotin to treat patients with relapsed or refractory multiple myeloma who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback